ECSP14011792A - Inhibidores de iap - Google Patents

Inhibidores de iap

Info

Publication number
ECSP14011792A
ECSP14011792A ECIEPI201411792A ECPI201411792A ECSP14011792A EC SP14011792 A ECSP14011792 A EC SP14011792A EC IEPI201411792 A ECIEPI201411792 A EC IEPI201411792A EC PI201411792 A ECPI201411792 A EC PI201411792A EC SP14011792 A ECSP14011792 A EC SP14011792A
Authority
EC
Ecuador
Prior art keywords
iap inhibitors
inhibitors
iap
useful
general formula
Prior art date
Application number
ECIEPI201411792A
Other languages
English (en)
Inventor
Lewis J Gazzard
Vickie Hsiao-Wei Tsui
John A Flygare
Frederick Cohen
Original Assignee
Genentech Inc
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Curis Inc filed Critical Genentech Inc
Publication of ECSP14011792A publication Critical patent/ECSP14011792A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Nuevos inhibidores de IAP que son de utilidad como agentes terapéuticos para tratar malignidades y tienen la fórmula general I: en donde R1,R2,R3,R4,R5 y R6 son como se describen en la presente.
ECIEPI201411792A 2012-01-03 2014-07-31 Inhibidores de iap ECSP14011792A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261582760P 2012-01-03 2012-01-03

Publications (1)

Publication Number Publication Date
ECSP14011792A true ECSP14011792A (es) 2015-12-31

Family

ID=48695302

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201411792A ECSP14011792A (es) 2012-01-03 2014-07-31 Inhibidores de iap

Country Status (41)

Country Link
US (6) US8716236B2 (es)
EP (2) EP3133073B1 (es)
JP (2) JP5747137B2 (es)
KR (3) KR101855566B1 (es)
CN (2) CN104159897A (es)
AR (2) AR089623A1 (es)
AU (1) AU2013202780B2 (es)
BR (1) BR112014016637B1 (es)
CA (1) CA2861637C (es)
CL (1) CL2014001770A1 (es)
CO (1) CO7020915A2 (es)
CR (1) CR20140367A (es)
CY (2) CY1118371T1 (es)
DK (2) DK2800749T3 (es)
EC (1) ECSP14011792A (es)
ES (2) ES2672809T3 (es)
HK (1) HK1203949A1 (es)
HR (2) HRP20161381T1 (es)
HU (2) HUE031305T2 (es)
IL (2) IL233386A (es)
LT (2) LT2800749T (es)
MA (1) MA35895B1 (es)
ME (2) ME03084B (es)
MX (1) MX336294B (es)
MY (1) MY178390A (es)
NO (1) NO2755614T3 (es)
NZ (1) NZ627480A (es)
PE (1) PE20142182A1 (es)
PH (2) PH12014501534A1 (es)
PL (2) PL3133073T3 (es)
PT (2) PT3133073T (es)
RS (2) RS55327B1 (es)
RU (2) RU2728789C2 (es)
SG (1) SG11201403784QA (es)
SI (2) SI2800749T1 (es)
SM (1) SMT201600357B (es)
TR (1) TR201808088T4 (es)
TW (1) TWI503318B (es)
UA (1) UA114417C2 (es)
WO (1) WO2013103703A1 (es)
ZA (1) ZA201405535B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2755614T3 (es) * 2012-01-03 2018-03-31
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
CN109705191B (zh) * 2017-10-25 2022-04-29 广东东阳光药业有限公司 Iap抑制剂及其在药物中的应用
PL3712162T3 (pl) * 2017-11-13 2022-11-14 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. MIMETYKI SMAC STOSOWANE JAKO INHIBITORY lAP I ICH ZASTOSOWANIE
US11639354B2 (en) 2018-07-31 2023-05-02 Fimecs, Inc. Heterocyclic compound
JPWO2021020585A1 (es) 2019-07-31 2021-02-04
MX2022008874A (es) 2020-01-20 2022-08-11 Astrazeneca Ab Inhibidores de la tirosina cinasa del receptor del factor de creciminto epidermico para el tratamiento del cancer.
WO2023239422A2 (en) 2021-10-22 2023-12-14 University Of Houston System Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancers of epithelial tissues

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
EP0975608B1 (en) 1997-04-15 2005-06-15 Genentech, Inc. Halo-alkoxycarbonyl prodrugs
KR100984459B1 (ko) * 2004-07-02 2010-09-29 제넨테크, 인크. Ｉａｐ의 억제제
ATE477254T1 (de) * 2004-12-20 2010-08-15 Genentech Inc Pyrrolidine als inhibitoren von iap
EP2102229B1 (en) 2006-10-12 2014-03-26 Novartis AG Pyrrolydine derivatives as iap inhibitors
MX2009011783A (es) 2007-04-30 2009-12-04 Genentech Inc Inhibidores de iap.
NO2755614T3 (es) 2012-01-03 2018-03-31
USD690416S1 (en) 2012-12-12 2013-09-24 Pharmajet, Inc. Needle-free syringe

Also Published As

Publication number Publication date
IL233386A (en) 2016-08-31
DK3133073T3 (en) 2018-06-18
CY1118371T1 (el) 2017-06-28
CY1120355T1 (el) 2019-07-10
CO7020915A2 (es) 2014-08-11
PT3133073T (pt) 2018-06-18
JP5747137B2 (ja) 2015-07-08
US9586991B2 (en) 2017-03-07
CA2861637A1 (en) 2013-07-11
CA2861637C (en) 2017-07-18
US8716236B2 (en) 2014-05-06
PE20142182A1 (es) 2015-01-16
HUE037760T2 (hu) 2018-09-28
BR112014016637B1 (pt) 2022-06-14
US11963994B2 (en) 2024-04-23
EP3133073B1 (en) 2018-05-02
TWI503318B (zh) 2015-10-11
SG11201403784QA (en) 2014-08-28
ES2594856T3 (es) 2016-12-23
US20170136084A1 (en) 2017-05-18
US11096982B2 (en) 2021-08-24
CN107915728A (zh) 2018-04-17
ME02526B (me) 2017-02-20
MX2014007895A (es) 2015-03-19
IL242314A (en) 2016-08-31
US20130172264A1 (en) 2013-07-04
KR20150065960A (ko) 2015-06-15
RS55327B1 (sr) 2017-03-31
CR20140367A (es) 2015-02-18
KR101855566B1 (ko) 2018-05-04
MY178390A (en) 2020-10-12
LT2800749T (lt) 2016-10-25
US20220211797A1 (en) 2022-07-07
PT2800749T (pt) 2016-10-24
RS57438B1 (sr) 2018-09-28
PH12014501534B1 (en) 2014-10-08
SMT201600357B (it) 2016-11-10
HUE031305T2 (hu) 2017-07-28
TR201808088T4 (tr) 2018-06-21
JP2015199738A (ja) 2015-11-12
KR101917992B1 (ko) 2018-11-13
UA114417C2 (uk) 2017-06-12
PL3133073T3 (pl) 2018-09-28
IL233386A0 (en) 2014-08-31
ME03084B (me) 2019-01-20
US20190224269A1 (en) 2019-07-25
PH12014501534A1 (en) 2014-10-08
EP2800749A4 (en) 2015-08-05
HRP20180976T1 (hr) 2018-08-10
CN107915728B (zh) 2021-04-30
AU2013202780A1 (en) 2013-07-18
WO2013103703A1 (en) 2013-07-11
RU2728789C2 (ru) 2020-07-31
SI2800749T1 (sl) 2016-11-30
RU2016124658A (ru) 2018-12-04
PH12015501038B1 (en) 2015-09-21
US20160102119A1 (en) 2016-04-14
AR089623A1 (es) 2014-09-03
TW201333001A (zh) 2013-08-16
RU2014130171A (ru) 2016-02-27
HK1203949A1 (en) 2015-11-06
LT3133073T (lt) 2018-06-25
EP3133073A2 (en) 2017-02-22
HRP20161381T1 (hr) 2016-12-02
EP2800749A1 (en) 2014-11-12
AU2013202780B2 (en) 2015-04-16
BR112014016637A8 (pt) 2017-07-04
KR20140107670A (ko) 2014-09-04
NZ627480A (en) 2016-04-29
ZA201405535B (en) 2017-08-30
CL2014001770A1 (es) 2015-04-17
AR123542A2 (es) 2022-12-14
DK2800749T3 (en) 2016-11-07
KR101553792B1 (ko) 2015-09-16
ES2672809T3 (es) 2018-06-18
JP2015504072A (ja) 2015-02-05
NO2755614T3 (es) 2018-03-31
CN104159897A (zh) 2014-11-19
EP2800749B1 (en) 2016-09-21
KR20180051646A (ko) 2018-05-16
EP3133073A3 (en) 2017-03-22
PH12015501038A1 (en) 2015-09-21
US20140235551A1 (en) 2014-08-21
BR112014016637A2 (pt) 2017-06-13
PL2800749T3 (pl) 2017-01-31
RU2593259C2 (ru) 2016-08-10
MA35895B1 (fr) 2014-12-01
MX336294B (es) 2016-01-14
SI3133073T1 (en) 2018-06-29
US9238675B2 (en) 2016-01-19
RU2016124658A3 (es) 2019-09-09

Similar Documents

Publication Publication Date Title
ECSP14011792A (es) Inhibidores de iap
UY34648A (es) Amidas como inhibidores de pim
MX356368B (es) Profarmacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
BR112015011830A2 (pt) compostos e seus métodos de utilização
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
BR112013002012A2 (pt) métodos e composições para terapia de câncer de fígado
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
EA201400178A1 (ru) Лечение рака молочной железы
BR112015011756A2 (pt) inibidores da glutamase e métodos de uso
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
DOP2014000033A (es) Aminoquinazolinas como inhibidores de quinasa
CR20150133A (es) Amino-quinolinas como inhibidores de cinasa
CR20150211A (es) Compuestos diméricos
DOP2015000060A (es) Profármacos de aminoquinazolina inhibidora de cinasa
MX2014015039A (es) Inhibidores de fbx03.
UY34043A (es) Isoxazolinas como agentes terapéuticos
ECSP16061208A (es) Quinazolin-thf-aminas como inhibidores de pde1
CR20150148A (es) Azaindolinas
EA201590615A1 (ru) Стимулирующие лактацию композиции на основе фосфатидилсерина
UA117809C2 (uk) Похідні бендамустину, споріднені сполуки та їхнє медичне застосування для лікування раку
MX346097B (es) Derivados de difenilo sustituidos.
UY34755A (es) Agentes para el control de la glycaspis brimblecombei